Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI:10.1080/14737140.2023.2157816

Yihua Zou, Yue Si, Fangqin Tong, Meng Guan, Chun Bi, Xia Wang

{"title":"Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials.","authors":"Yihua Zou, Yue Si, Fangqin Tong, Meng Guan, Chun Bi, Xia Wang","doi":"10.1080/14737140.2023.2157816","DOIUrl":null,"url":null,"abstract":"Background: Neovascularization is an important factor causing radiotherapy resistance, tumor growth, and metastasis. It may provides a new direction for treatment of cervical cancer.Objective and methods: The main objective is to systematically evaluate the clinical efficacy and safety of antiangiogenic therapy combined with CCRT in the treatment of cervical cancer. We searched major Chinese and English databases to collect relevant studies from the database establishment up to April 2022. The experimental group of the studies included used CCRT combined with anti-angiogenic therapy, while another used only CCRT. We used the 'Cochrane Collaboration's tool' to assess risk of bias and RevMan 5.4 to conduct analysis.Results: Twelve studies with 793 patients were included. Use clinical efficiency and adverse reactions as effect indicators. It showed that the combination can improve the ORR (OR = 3.52, P < 0.00001), CR(OR = 2.46, P < 0.00001), DCR (OR = 2.64, P= 0.005), and OS(HR = 0.56, P = 0.03). But it increases the risk of neutropenia (OR = 1.86, P = 0.004) and hypertension (OR = 5.57, P = 0.003).Conclusions: Combined therapy can improve the clinical efficacy of cervical cancer, but the safety needs to be considered.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 2","pages":"217-227"},"PeriodicalIF":2.9000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2157816","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neovascularization is an important factor causing radiotherapy resistance, tumor growth, and metastasis. It may provides a new direction for treatment of cervical cancer.

Objective and methods: The main objective is to systematically evaluate the clinical efficacy and safety of antiangiogenic therapy combined with CCRT in the treatment of cervical cancer. We searched major Chinese and English databases to collect relevant studies from the database establishment up to April 2022. The experimental group of the studies included used CCRT combined with anti-angiogenic therapy, while another used only CCRT. We used the 'Cochrane Collaboration's tool' to assess risk of bias and RevMan 5.4 to conduct analysis.

Results: Twelve studies with 793 patients were included. Use clinical efficiency and adverse reactions as effect indicators. It showed that the combination can improve the ORR (OR = 3.52, P < 0.00001), CR(OR = 2.46, P < 0.00001), DCR (OR = 2.64, P= 0.005), and OS(HR = 0.56, P = 0.03). But it increases the risk of neutropenia (OR = 1.86, P = 0.004) and hypertension (OR = 5.57, P = 0.003).

Conclusions: Combined therapy can improve the clinical efficacy of cervical cancer, but the safety needs to be considered.

查看原文本刊更多论文

抗血管生成药物联合放化疗治疗局部晚期宫颈癌的疗效和安全性:一项随机对照试验的荟萃分析

背景:新生血管是引起放疗抵抗、肿瘤生长和转移的重要因素。这可能为宫颈癌的治疗提供新的方向。目的与方法:主要目的是系统评价抗血管生成疗法联合CCRT治疗宫颈癌的临床疗效和安全性。我们检索了主要的中文和英文数据库，收集了截至2022年4月数据库建立的相关研究。实验组采用CCRT联合抗血管生成治疗，另一组仅采用CCRT治疗。我们使用“Cochrane协作工具”评估偏倚风险，并使用RevMan 5.4进行分析。结果:纳入12项研究，793例患者。以临床疗效和不良反应为效果指标。结果表明，联合用药可提高ORR (OR = 3.52, P= 0.005)和OS(HR = 0.56, P= 0.03)。但它增加了中性粒细胞减少症(OR = 1.86, P = 0.004)和高血压(OR = 5.57, P = 0.003)的风险。结论:联合治疗可提高宫颈癌的临床疗效，但需考虑安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.